Pharmafile Logo

Creative Biogene

Creative Biogene is the leading global client service and solutions provider for scientific research, and is committed to the development, manufacture and purification of recombinant adenoviruses, adeno-associated virus (AAV) and lentivirus for gene delivery and gene knock down. With above 20 years of gene delivery tools development experience, Creative Biogene is specialized in providing gene delivery and gene knock down services that cover the full scope of biotechnology needs of early drug discovery and drug development.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.

View Profile

Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys ‘boots-on-the-ground’ recruitment experts in over 70 countries, addressing individual sites’…

View Profile

Company Details

45-16 Ramsey Road Shirley, New York, NY 11967, United States
+1 631 624 4882

 Latest Content from PMHub 

Lucid Group announces the appointment of a new Legal and Compliance manager

Lucid Group demonstrates continual investment in its infrastructure by appointing Sebastian Goodwin as its new Legal and Compliance manager.Sebastian studied politics and trained to be a lawyer before moving into...

Lucid Group Experience the Magic of Mindfulness, Meditation and Massage

This time of year can be busier than normal. Lucid Group understand the importance of taking some time out to relax and unwind. That's why yesterday, relaxation, meditation and mindfulness...

Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?

A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....

Bedrock’s on fire for Wellbeing Week

Bedrock creates a positive working environment to enable individuals and our business to thrive.

WHITE PAPER: Patient nonadherence – the $637bn paradox

White Papers and Resources | November 25, 2019 | IGNIFI

What’s not changed for 50 years, kills 200,000 Europeans annually, costs pharma $637 billion and the NHS over £500 million a year? We’ll tell you.

Spotlight interview: 15 minutes on insights and market research in pharma

Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma

Early diagnosis underpins NHS cancer strategy

Paul Midgley, Oli Hudson and Sarah Shield, of Wilmington Healthcare, explore how the NHS is tackling cancer in line with the Long-term Plan

Launch Excellence 2020

In this special pack, we provide a comprehensive outlook of launch excellence. We cover topics ranging from gathering effective insights, to understanding the current landscape, and the importance of pre-launch...

OPEN Health reflections on the World Orphan Drug Congress in Barcelona

Having just returned from a very busy but hugely enjoyable few days at congress, I wanted to share our views on the event and key themes that our healthcare communications...

Antibiotic resistance: The silent pandemic

Porterhouse is proud to support World Antibiotic Awareness Week. Our article aims to improve awareness of one of the biggest threats to global health today: antibiotic resistance.